Evidence map›Paper›PMID 9916932›Full record

ArticleThe American journal of pathology1999

WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.

Y Yang, C Jeanpierre, G R Dressler, M Lacoste, P Niaudet, M C Gubler

Open access · greenAbstract read
In one paragraph

Article in The American journal of pathology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 114 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. The Pathology Lesion Patterns of Podocytopathies: How and why?Frontiers in cell and developmental biology · 2022
    Review
  8. A novel WT1 gene mutation in a chinese girl with denys-drash syndrome.Journal of clinical laboratory analysis · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. PAX2 in human kidney malformations and disease.Pediatric nephrology (Berlin, Germany) · 2012
    Review
  13. Article
  14. Progress in pathogenesis of proteinuria.International journal of nephrology · 2012
    Article
  15. Review
  16. Molecular and genetic basis of inherited nephrotic syndrome.International journal of nephrology · 2011
    Article
  17. Article
  18. Nephrin deficiency activates NF-kappaB and promotes glomerular injury.Journal of the American Society of Nephrology : JASN · 2009
    Article
  19. Article
  20. Ectopic notch activation in developing podocytes causes glomerulosclerosis.Journal of the American Society of Nephrology : JASN · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Y YangINSERM U.423, Hôpital Necker-Enfants Malades, Université René Descartes, Paris, France.
C Jeanpierre
G R Dressler
M Lacoste
P Niaudet
M C Gubler
Hôpital Necker-Enfants Malades · FRUniversité Paris Cité · FRHoward Hughes Medical Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Denys-Drash syndrome is a rare disorder of urogenital development characterized by the association of early onset glomerulopathy caused by diffuse mesangial sclerosis, gonadal dysgenesis leading to pseudohermaphroditism in males, and a high risk of developing Wilms' tumor. The syndrome is caused by dominant negative point mutations in the WT1 gene that encodes a tumor suppressor transcription factor normally expressed in podocytes. Mutations usually affect the zinc fingers of the WT1 protein. The basic defect is unknown in most cases of isolated diffuse mesangial sclerosis, a disease characterized by the same glomerular changes as in Denys-Drash syndrome but possibly transmitted as an autosomal recessive trait. Here we show that the distribution of WT1 is abnormal in most patients with Denys-Drash syndrome : WT1 nuclear staining of podocytes is decreased or absent. This finding is consistent with the decreased DNA binding capacity of the mutated protein. One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis. We demonstrate that WT1 mislocalization is associated with abnormal podocyte expression of PAX2 protein and RNA. We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction. Abnormal distribution of WT1 and PAX2 was also observed in isolated diffuse mesangial sclerosis suggesting that a defect in WT1 could also be operative in isolated diffuse mesangial sclerosis. Primary involvement of PAX2 is an alternative hypothesis because persistent expression of PAX2 in transgenic mice is associated with the occurrence of early and severe glomerulopathy.

Indexed as

Male Urogenital DiseasesAnimalsDevelopmental DisabilitiesDNA-Binding ProteinsFemaleFemale Urogenital DiseasesFetusGenitaliaGlomerular MesangiumGlomerulosclerosis, Focal SegmentalHumansInfant, NewbornKidney DiseasesKidney GlomerulusMalePAX2 Transcription FactorDNA-Binding ProteinsPAX2 protein, humanPAX2 Transcription FactorTranscription FactorsWT1 Proteins

Identifiers

PMID9916932
PMCPMC1853439
OpenAlexW2160453337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.